An antibody-based platform for melatonin quantification

Publication date: Available online 7 July 2018Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Laís C. Brazaca, Camila B. Bramorski, Juliana Cancino-Bernardi, Sanseray da Silveira Cruz-Machado, Regina P. Markus, Bruno C. Janegitz, Valtencir ZucolottoAbstractMelatonin, the ‘chemical signal of darkness’, is responsible to regulate biological rhythms and different physiological processes. It is mainly produced by the pineal gland as a hormone in a rhythmic daily basis, but it may also be synthesized by other tissues, such as immune cells, under inflammatory conditions. Its abnormal circulating levels have been related to several diseases such as type 2 diabetes, Alzheimer’s disease and some types of cancer. Currently, melatonin is exclusively quantified by ELISA or radioimmunoassays, which although are very sensitive techniques and present low detection limits, usually require specialized personal and equipment, restricting the tests to a limited number of patients. To overcome such limitations, we developed a novel easy-to-use electrochemical immunosensor for rapid melatonin quantification. Anti-melatonin antibodies were immobilized into Indium tin oxide (ITO) platforms using (3-Aminopropyl)triethoxysilane (APTES), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS) crosslinkers. The platforms were assayed with synthetic and biologically-present melatonin containing samples. The developed device displayed a linear response in the co...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research